怎样治疗头皮湿疹

如何治疗头皮湿疹配图，仅供参考

3.2.1. Topical Medication
A. Topical Corticosteroids (TCSs) have been the mainstay treatment for AD. They suppress many inflammatory cells and cytokines,including neutrophils,monocytes,lymphocytes,LCs,IL2,TNF,and GM-CSF,resulting in anti-inflammatory and immunosuppressive effects. They are widely used and have been the recommended first-line therapy for acute exacerbation of AD for several decades. In general,it has been suggested that the application of TCSs should start with the lowest potency agents and should take the duration of usage into consideration. Application is recommended once or twice daily within a period of several weeks,depending on the different potencies of the agents,and prolonged use is not recommended .
B. Topical calcineurin inhibitors (TCIs),such as pimecrolimus and tacrolimus function by binding to the intracellular protein macrophilin-12,suppressing calcineurin activity,and inhibiting mast cell and neutrophil activation . Pimecrolimus is indicated for use in mild to moderate AD,while tacrolimus is indicated for use in moderate to severe AD. Compared with pimecrolimus,tacrolimus has superior efficacy due to its greater affinity for FK506-binding proteins and better long-term results when used as monotherapy. A meta-analysis,including 14 trials involving 7376 children and adults with AD,demonstrated that both TCIs have favorable efficacy but more adverse events than TCIs . Mild to moderate burning sensations and pruritus are two common adverse events and are generally resolved within one week of treatment initiation,for treatment using both tacrolimus and pimecrolimus.","department":"